Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 20 December 2010
Thank you for submitting your manuscript to the EMBO Journal. Your study has now been seen by three referees and their comments to the authors are provided below.
As you can see below, the referees appreciate the characterization of the IgH-hypomorphic mutant mice and the finding that BCR signaling strength affects B-cell development. However they also find that some further characterization of the mice is needed for publication here. Should you be able to address the raised concerns in full then I would like to invite you to submit a revised manuscript for our consideration. I should remind you that it is EMBO Journal policy to allow a single major round of revision only and that it is therefore important to address the raised concerns at this stage. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal
REFEREE REPORTS
Referee #1 (Remarks to the Author):
The manuscript from Winkler's group reports on the detailed analysis of a targeted mutant mouse that expresses significantly less IgHC mRNA than wild-type mice. The mouse was generated with the intention of creating a GFP reporter allele for Ig transcription, but instead the result was a mouse that lacked GFP expression but displayed a B cell development phenotype associated with a decrease in BCR expression levels. Their analysis of this mouse revealed partial developmental blocks at the pro-to-pre, pre-to-immature, and immature to various mature subset transitions. Their data is strong, clearly presented and well controlled. This paper would be of interest to the subset of your readers that study lymphocyte development.
The authors should consider the following points:
1) Is it fair to consider the increase in Ig light chain locus rearrangement in mutant pre-B cells to be the equivalent of receptor editing and supportive of one mechanistic model for the regulation of editing? Another interpretation is that the V(D)J recombinase remains active until the cells senses a specific level of tonic BCR signaling. This level might not be achieved in most cases leading to a failure to inactivate the recombinase.
2) The authors suggest that their approach allows one to study plasma cells in the absence of the unfolded protein response. In PCs, and in other cells in this study, might the unmatched levels of IgHC and IgLC gene expression result in the accumulation of unfolded IgLC and the UPR? Authors should comment.
3) Fig. 4D : Ca flux measurement lacks an essential control: treatment with ionomycin to ensure equal loading of the two samples with Indo-1! This same figure lacks units on both x and y axis. This needs to be given to indicate the scale of the differences observed between the two mice. Also, only the sustained Ca flux is impaired, not the initial Ca response. This point should be discussed. Fig. 4D : The authors interpret their data to indicate that tonic BCR signaling strength (as affected by hypomorphic HC expression) rather than antigen specificity influences the cell fate of B cell subsets in naive mice. However, Fab2 stimulation in Fig. 4 D leads to BCR crosslinking and mimics antigen binding. Therefore, this is not an ideal experiment to analyse tonic BCR signaling strength. data in Fig. 4D should be verified by using Pervanadat treatment and PY-specific antibodies in FACS or Western blotting. Fig. 5D : lacks a negative staining control to discriminate whether or not LPS-treated B cells from EmuGFP/EmuGFP mice express muHC proteins at all. And if so, do they express exclusively the membrane form or also the secretory form of muHC proteins? There seems to be a defect in the switch between these two muHC splice forms, as the authors hypothesize, but this could be easily tested without much effort. This figure could be improved by gating on specific subpopulations of B cells, such as MZ and FO etc, and analyzing their muHC expression level.
4)

Minor comments
5) The last sentence of the abstract makes no sense 6) The reason for lack of GFP expression is unclear: the authors mention it might be due to the usage of destabilized GFP, yet this protein is usually expressed at low but detectable levels. Perhaps upstream ATGs in Emu that lead to out-frame translational initiation...? 7) Fig. 6 legend mentions BM (Left), spleen (middle), PC ‚(right). However, actual layout of figure is BM(top), spleen (middle), PC (bottom). Also, the legend should give a little more information on how the comp. BM chimara experiment was performed, i.e. which cells were mixed (defined by Ly5 allotypes) and transferred into what mouse.
8) In fig. 6 BM, there does not seem to be a significant difference at the transition from small pre-B to immature B cells. However, the text mentions there is a difference. Please clarify.
Referee #2 (Remarks to the Author):
In this manuscript from Brenner et al., the authors have generated a hypomorphic Igµ heavy chain expressing mouse and observe a number of developmental defects both in the bone marrow and the periphery.
The most interesting data in this manuscript is the increase in receptor editing seen in the mutant mouse as evidenced by an increase in the λ light chain usage and in Jκ5 usage. This is not explored further in a mechanistic sense. This data fits with a hypothesis (quoted by the authors) of reduced tonic BCR signaling and the consequent failure to shut off Rag gene expression resulting in reversion to a pre-B like phenotype. The likely loss of tonic signaling in B cells should be tested to examine whether there is a failure to shut off Rag gene expression at the immature B cell stage.
The marginal zone and follicular B cell differentiation data remains somewhat equivocal although they are discussed at length. Clearly the apparently strong Ca++ flux seen in the hypomorphic mutant mouse does not fit with the data on B cell development, and clearly the anti-IgM concentration should be significantly titrated down for these studies to be meaningful.
Referee #3 (Remarks to the Author):
In the paper Brenner et al. characterize B-cell development in the context of hypomorphic IgH-chain in mice. By insertion of polyA-signal element downstream of heavy chain intronic enhancer, expression of the heavy chain locus is dramatically decreases, but is not completely abrogated, and leads to reduction of the surface expression of pre-BCR and BCR on respective cell populations. The authors report on strong block in B-cell development in hypomorphic homozygote mice with particular effect on development of follicular B-cells in the spleen and the B1a cell population in the peritoneal cavity. The authors also disclose strong reduction in serum antibody levels together with abrogated immunoglobulin serum titers after immunization with TI antigen. In vivo experiments on IgH-hypomorphic mice are substantially complemented by rescue of the reported B1a cell developmental loss by crossing IgHEµ-GFP/Eµ-GFP mice to mice, having additional mutations in BCR-signal regulating molecules, SiglecG-/-and plcγ2+/Ali5, as well as well as by experiments with competitive BM chimeras. IgHEµ-GFP/Eµ-GFP mice is an interesting in vivo experimental model for addressing antigen receptor mediated signals in B-cell development, however its further characterization is required. Comments 1. Although authors claim that the phenotype of IgHEµ-GFP/Eµ-GFP hypomorphic mice is a result of impaired signaling from the pre-BCR and BCR, they show only one Ca-flux experiment after antigen stimulation (Fig. 4D) , where speed and amplitude of the Ca-response to BCR stimulation does not differ between IgHEµ-GFP/Eµ-GFP and IgHb/b MZ B-cells. Brenner et al. present IgHEµ-GFP/Eµ-GFP hypomorphic mouse model with advantage of nonrestricted receptor repertoire as the best so far to address receptor signal-strength model for B-cell development, selection and survival. Therefore it would be required to characterize in more detail BAFF-R pathway with noncanonical NF-kB, PI3K pathway, and key molecules downstream of receptor, mediating cell survival, like bcl-2. 2. IgHEµ-GFP allele has a strong polyA-signal sequence downstream of the IgH chain intronic enhancer, which interferes with transcription taking place in the locus. In table 1 and Fig.S3 authors discuss µHC mRNA levels but never show qrt-pcr results directly. For description of the IgHEµ-GFP hypomorphic locus it would be generally important to characterize sterile transcripts from the IgHEµ-GFP locus. VDJ recombination in the HC locus is strongly linked with transcription in the locus. Therefore, direct characterization of the sterile transcripts from the IgHEµ-GFP locus should provide more justified argumentation with respect to intact VDJ recombination in IgHEµ-GFP locus, as it is claimed in the manuscript. Results of experiment on HC locus allotype usage for excluding impairment in VDJ-recombination ( Fig. S2B ), are already biased for J558 Vh family in the heterozygote control, and therefore inconclusive. 3. Authors report that B1a-cell development in IgHEµ-GFP/Eµ-GFP mice is rescued on SiglecG-/-and plcγ2+/Ali5 backgrounds, and do not disclose if this is selective only for B1a cells. It would be also required to report on whether IgHEµ-GFP/Eµ-GFP B2 B-cell development is rescued on the plcγ2+/Ali5 background. 4. It would be required to proofread last sentence of the abstract. Referee #1:
We like to thank the referee 1 for the positive evaluation. We would like to respond to the comments as below:
Main comments: 1) Is it fair to consider the increase in Ig light chain locus rearrangement in mutant pre-B cells to be the equivalent of receptor editing and supportive of one mechanistic model for the regulation of editing? Another interpretation is that the V(D)J recombinase remains active until the cells senses a specific level of tonic BCR signaling. This level might not be achieved in most cases leading to a failure to inactivate the recombinase.
Response:
We fully agree with the referee's notion. It is also our interpretation that the VDJ recombinase remains active when a certain threshold of tonic BCR signaling cannot be reached, and this level less frequently is achieved in the mutant mice. We like to point out that this hypothesis is mentioned explicitly at the beginning of the respective paragraph of the results section and is taken up in our discussion. In the field, the term receptor editing is indeed used for both self-antigen driven "reinduction" of Rag expression as well as for the failure to downregulate Rag expression due to lowerthan-threshold levels of tonic BCR signaling (Nemazee 2003 , Tze et al., 2005 , both references are cited).
2) The authors suggest that their approach allows one to study plasma cells in the absence of the unfolded protein response. In PCs, and in other cells in this study, might the unmatched levels of IgHC and IgLC gene expression result in the accumulation of unfolded IgLC and the UPR? Authors should comment.
In our manuscript at the end of the discussion we pointed out that the mutant mice are suitable to study plasma cell differentiation in the absence of the UPR. We have to admit that the last sentence can lead to misunderstandings and changed the sentence. Regarding the analysis of tonic BCR signaling, we were grateful for the reviewer's advice to perform experiments with pervanadate. As expected by the work of Wienands et al., 1996, addition of pervanadate enhanced the intracellular levels of phosphorylated proteins both in wildtype and mutant primary splenic B-lymphocytes as measured by FACS. We were unable to detect any significant differences in the PY-signals, however. As pervanadate treatment inhibits all cellular protein-phosphatases subtle differences in tonic signaling from the BCR originating from subtle differences in the BCR-levels might be below the detection limit in this approach. With respect to space limitations in our manuscript and in the light of the interesting data regarding BAFF-R expression we like to suggest to omit these data in the revised version. We will provide the FACS data as separate 'referee-only' supplementary material, however. We agree that a staining control was necessary to include in the Figure displaying LPS-activation ( Figure 7D ). This is changed now and we performed experiments with sorted MZ and FO cells which are included now.
Minor comments 5) The last sentence of the abstract makes no sense
Response: We apologize for this, this fragment somehow got included during final editing of our previous manuscript.
6) The reason for lack of GFP expression is unclear: the authors mention it might be due to the usage of destabilized GFP, yet this protein is usually expressed at low but detectable levels. Perhaps upstream ATGs in Emu that lead to out-frame translational initiation...?
Response: We now included a FACS analysis that shows the low but detectable levels of GFP in Suppl. Figure 1C . Fig. 6 1x10 6 splenic cells were incubated in 500μl RPMI-medium without supplements at 37°C for 1 hour. After centrifugation, cells were stained with α-CD21-FITC, purified α-CD16/32 and α-CD23-bio in PBS / 2%FCS for 30 min at 4°C followed by a 15min incubation step with streptavidine-Cy5 (antibodies and fluorochrome conjugates were purchased from eBioscience). Cells were washed with PBS / 2% FCS and resuspended in 500μl RPMI without supplements. Cells were then pre-incubated for 5min at 37°C. 8μl pervanadatesolution (prepared freshly by mixing equal amounts of solution A [10μl 30% H2O2 + 870μl H2O] and solution B [100mM Na3VO4]) was added to the cells. After incubation for 7min at 37°C, the reaction was stopped by adding 500μl 4% paraformaldehyde in PBS. After incubation at room temperature for 10min, cells were centrifuged and washed in PBS / 2% FCS. For permeabilization, cells were resuspended in 200μl ice-cold 90% methanol in PBS and incubated for 30min at 4°C. After one washing step in PBS / 2% FCS, cells were incubated with α-pTYR-PE (BD) at 4°C for 60min. Cells were washed and resuspended in PBS / 2% FCS and analyzed with a FACS-Calibur (BD).
7)
Referee #2:
We like to thank the referee 2 for his evaluation. We would like to respond to the comments as below: Figure 4) . We discuss these data in the discussion as the result of undetectable levels of surface IgM in preB-like cells that undergo receptor editing.
The marginal zone and follicular B cell differentiation data remains somewhat equivocal although they are discussed at length. Clearly the apparently strong Ca++ flux seen in the hypomorphic mutant mouse does not fit with the data on B cell development, and clearly the anti-IgM concentration should be significantly titrated down for these studies to be meaningful.
Response: As pointed out as response to reviewer 1 we did the Ca flux experiments mainly because we wanted to analyze whether lower BCR levels would translate in grossly altered BCR signaling after BCR crosslinking. This was true reproducibly the case only for marginal zone B cells, as predicted by slightly reduced BCR levels on MZ cells but similar IgM-levels on FO cells. We also titrated the stimulating anti-IgM antibody and got similar results as the one shown in Fig. 3D . We agree with the referee that the Ca flux data in the hypomorphic mutant mice does apparently not reflect the data on B cell development. We believe that with our new data on BAFF-R expression and reduced survival upon BAFF stimulation in vitro we can provide an explanation for the reduced mature B cell compartment in the mutant mice.
Referee #3:
We like to thank the referee 3 for his evaluation and are particularly grateful for some important suggestions, especially regarding BAFF-receptor expression and responsiveness. We would like to respond to the comments as below: (Fig. 4D) Response: These suggestions from the referee were very helpful. We have analyzed BAFF-R expression in the mutant B cells and found lower BAFF-R in the peripheral B-cell populations as well as less BAFFinduced survival in vitro. We think that these new data are very important additions to our manuscript and we added another Figure (Figure 6 ) to appreciate this and discuss the new results in the results section, page 14-15. The detailed analysis of the noncanonical NF-kB and PI3K pathway would, in our opinion, clearly be beyond the scope of our current manuscript, particularly as the differences can be expected to be quite small, and would need extensive experimentation. In addition our current manuscript is already at the space limit of text allowed. (Fig. S2B) , are already biased for J558 Vh family in the heterozygote control, and therefore inconclusive. Response: We like to point out that the Q-RT-PCR results are based on a comprehensive quantitative analysis with normalization of cDNA to β-actin (as described in the material and methods). From this analysis relative quantities of µHC mRNA were calculated and presented in Table 1 . Regarding VDJ-recombination, we believe that our analysis (now in Suppl. Fig. 3 ) does in fact provide good evidence for normal (i.e. comparable to a wildtype IgH a allele) recombination at the level of VDJ-recombination-products. The relative intensities of the AflII-digested amplicons from the mutant and the wildtype α-allele (which are derived from the non-functional allele) in comparison to the undigested b-alleles (which are derived from the expressed alleles in the sorted IgMb-positive B-cell populations) are comparable. For the 7183 amplicons, the (digested) IgHa alleles have similar intensities as the undigested IgHb alleles, for both the wt and the mutant alleles. For the J558 amplicons, the digested IgHa alleles show less intensive bands, both for wt-control and mutant IgMa alleles. The different proportions of IgMa/IgMb alleles among 7183 and J558 amplicons can be interpreted by the fact that 7183 genes are more frequently recombined but less frequently found in the expressed ("normalized") repertoire (for example shown by ten Boekel et al., Immunity 7:357, 1997). On the VDJ -alleles the VHJ558 family is underrepresented, while the VH7183 family appear overrepresented. Importantly, the mutant and wt IgMa alleles behave very similar in our analysis, ruling out major defects in the VDJrecombination of proximal (7183) or distal (J558) gene segments. We changed a sentence in the respective results section to make the argument more clear.
In the paper Brenner et al. characterize B-cell development in the context of hypomorphic IgHchain in mice. By insertion of polyA-signal element downstream of heavy chain intronic enhancer, expression of the heavy chain locus is dramatically decreases, but is not completely abrogated, and leads to reduction of the surface expression of pre-BCR and BCR on respective cell populations. The authors report on strong block in B-cell development in hypomorphic homozygote mice with particular effect on development of follicular B-cells in the spleen and the B1a cell population in the peritoneal cavity. The authors also disclose strong reduction in serum antibody levels together with abrogated immunoglobulin serum titers after immunization with TI antigen. In vivo experiments on
IgHEµ-GFP allele has a strong polyA-signal sequence downstream of the IgH chain intronic enhancer, which interferes with transcription taking place in the locus. In table 1 and Fig.S3 authors discuss µHC mRNA levels but never show qrt-pcr results directly. For description of the IgHEµ-GFP hypomorphic locus it would be generally important to characterize sterile transcripts from the IgHEµ-GFP locus. VDJ recombination in the HC locus is strongly linked with transcription in the locus. Therefore, direct characterization of the sterile transcripts from the IgHEµ-GFP locus should provide more justified argumentation with respect to intact VDJ recombination in IgHEµ-GFP locus, as it is claimed in the manuscript. Results of experiment on HC locus allotype usage for excluding impairment in VDJ-recombination
Authors report that B1a-cell development in IgHEµ-GFP/Eµ-GFP mice is rescued on SiglecG-/-and plcγ2+/Ali5 backgrounds, and do not disclose if this is selective only for B1a cells. It would be also required to report on whether IgHEµ-GFP/Eµ-GFP B2 B-cell development is rescued on the plcγ2+/Ali5 background.
Response: The B2 B-cell development in the spleen of double-mutant was analyzed and showed no rescue as compared to in IgHEµ-GFP/Eµ-GFP mice. This notion is now added in the text.
It would be required to proofread last sentence of the abstract.
Response: We apologize for this, this fragment somehow got included during final editing.
2nd Editorial Decision 21 April 2011
Thank you for submitting your revised manuscript to the EMBO Journal. I asked the original referees #2 and 3 to review the revised version and I have now received their comments. Referee #2 is satisfied with the revised version, while referee #3 has some issues to be addressed. The remaining concern raised by referee #3 is that there is not enough data provided to support the link between BCR signaling strength and B-cell linage development. The referee suggests a number of different experiments that would strengthen the findings reported. Given the comments provided, I would like to ask you to address/respond to the remaining concerns in a final round of revision.
Thank you for submitting your manuscript to the EMBO Journal.
Editor
The EMBO Journal REFEREE REPORTS Referee #2:
Revisions are adequate. Accept.
Referee #3:
In the revised version of the manuscript Brenner et al. claim that their IgHEmGFP/EmGFP mouse model is useful to study role of (tonic) receptor signaling in B-cell development, and respective animal model would support signal-strength receptor signaling model of lineage-specific B-cell development. Although authors report extensive analysis on several developmental blocks in B-cell development in IgHEmGFP/EmGFP mice, they never document any readout that would directly link lower receptor expression and attenuated tonic receptor signaling, which would be critical evidence for their main message. Data on BAFF-R expression and in vitro survival response upon BAFF administration cannot account for developmental blocks observed before BAFF-R positive stages and would even put aside the argument on importance of tonic signaling from antigen receptor as determinant for mature B cell survival. Therefore, it would be required to perform an experiment on addressing the extent on receptor signaling pathways at stages of B-cell development with the most prominent developmental blocks. Referee #2:
We like to thank the referee for his/her evaluation.
Referee #3:
In We agree with the referee's notion that tonic receptor signalling was not directly measured biochemically in our paper. Accordingly we changed our abstract at one position and the discussion at three positions to avoid overinterpretation. We like to point out, however, that almost all available data in the field regarding "tonic" i.e. constitutive signalling of the BCR are derived from genetic data. Current methodology, for example by rather unphysiological treatment with pervanadate is not able to measure the subtle differences in tonic signalling events in primary B-lymphocytes which can be expected in our hypomorphic IgH-mice. We don´t agree with the notion that one can conclude that other B cell populations are not dependent on PLCy-dependent signalling. The underlying mechanism of the Ali5 mutation (Yu et al., cited in our manuscript) is a gain-of-function mutation in PLCy2, which leads to hyperreactive external calcium entry in B cells, in the context of our hypomorphic mice normalizing specifically B1a cell populations. PLCy2 deficient mice have strong phenotypes in other cell types as well, as has been documented before. Regarding SHP-1 knockdown or knock-out experiments: First, the role of SHP-1 as a negative regulator in pre-BCR signalling must be questioned, as SHP-1 deficient mice to our knowledge show no pre-B-cell phenotype. This is even unlikely as SHP-1 is recruited by CD22, which is not yet expressed in pre-B cells. Second: In SHP-1 deficent mice all B-cells develop into B1 cells. Therefore these experiments would not result in any further mechanistic insight in our hypomorphic IgH mutant mice with rather subtle differences in BCR-expression levels. 
